Anavex Life Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 40
- Market Cap
- $515.5M
- Website
- http://www.anavex.com
- Introduction
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Anavex Life Sciences Corp.
- Target Recruit Count
- 32
- Registration Number
- NCT02244541
- Locations
- 🇦🇺
Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Caulfield Hospital, Melbourne, Victoria, Australia
🇦🇺Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath